Retrieved on:
Monday, December 18, 2023
Physician,
Research,
FDA,
Acquisition,
Transaction,
Prostate cancer,
Cancer,
BWB,
LDT,
Patient,
BPH,
Therapy,
Management The acquisition of Proteomedix for all stock consideration provides its shareholders with an initial 19.9% ownership stake of Onconetix.
Key Points:
- The acquisition of Proteomedix for all stock consideration provides its shareholders with an initial 19.9% ownership stake of Onconetix.
- Two members of Proteomedix’ leadership team will become executives of Onconetix.
- “This pivotal move not only expands our global footprint, it enables us to harness the advanced technological platform and diagnostic expertise of Proteomedix.
- Tungsten Advisors served as the exclusive financial advisor to Proteomedix AG.
Retrieved on:
Thursday, August 10, 2023
Biotechnology,
Insurance,
Consultant,
Advertising,
Letter,
Pharmacy,
Acquisition,
Bluewater,
Patient,
Marketing,
Health insurance CINCINNATI, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biotechnology and pharmaceutical company spanning multiple sectors, today announced the signing of an agreement with Copay Consultants, LLC (“Copay Consultants”) to build copay assistance programs for Blue Water’s commercial products, including ENTADFI®, which was acquired in April and ZONTIVITY®, which is expected to be acquired in the coming weeks after the signing of an asset purchase agreement in June.
Key Points:
- CINCINNATI, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biotechnology and pharmaceutical company spanning multiple sectors, today announced the signing of an agreement with Copay Consultants, LLC (“Copay Consultants”) to build copay assistance programs for Blue Water’s commercial products, including ENTADFI®, which was acquired in April and ZONTIVITY®, which is expected to be acquired in the coming weeks after the signing of an asset purchase agreement in June.
- Copay Consultants team has over 40 years of combined experience in the life science industry, including creation of manufacturer sponsored patient savings programs, pharmacy adjudicated copay discount programs, direct to patient rebates, patient web enrollment and attestation services, patient messaging, among others.
- In this new effort, Blue Water’s commercial team will work closely with Copay Consultants to design and implement a copay assistance program for eligible ENTADFI® and ZONTIVITY® patients.
- Recent execution includes significant progress with Blue Water collaborators and vendors across sales, marketing, advertising, telehealth development, market access, and sample distribution.
Knipper Health has more than 35 years of experience building and maintaining operations for healthcare clients, including sample management, custom pharmacy solutions and 3PL services.
Key Points:
- Knipper Health has more than 35 years of experience building and maintaining operations for healthcare clients, including sample management, custom pharmacy solutions and 3PL services.
- As part of Blue Water’s product roll-out plans, Knipper Health will oversee sample inventory and ship samples on request to the sales force in the field.
- Most importantly is our collaboration with proven industry partners such as Knipper Health, that will help to make the product launches successful.
- Blue Water has executed agreements that cover market access and payor coverage, marketing and advertising, telehealth services generation and sales force development.
CINCINNATI, July 25, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a biotechnology and pharmaceutical company focused on developing and commercializing transformational therapies to address significant health challenges globally, today announced an agreement with UpScriptHealth (“UpScript”) to generate a robust, online telemedicine platform to distribute Blue Water’s benign prostatic hyperplasia (“BPH”) asset, ENTADFI®.
Key Points:
- CINCINNATI, July 25, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a biotechnology and pharmaceutical company focused on developing and commercializing transformational therapies to address significant health challenges globally, today announced an agreement with UpScriptHealth (“UpScript”) to generate a robust, online telemedicine platform to distribute Blue Water’s benign prostatic hyperplasia (“BPH”) asset, ENTADFI®.
- Under this agreement, UpScript will build an online platform to support BPH patients throughout the prescription and coverage process, as well as provide eligible patients access to ENTADFI® mailed directly to their homes.
- This agreement with UpScript represents a milestone reached by Blue Water in its efforts to launch its commercial portfolio, highlighted by ENTADFI®, that was previously announced in a letter to shareholders from Mr. Hernandez earlier this month.
- With the official launch of ENTADFI® scheduled in the coming months, Blue Water’s commercial team is executing on key strategies including sales force development, distribution capabilities, as well as marketing and advertising development.
Telehealth,
Business development,
Senior,
Marketing,
Wake (Dead Can Dance album),
IQVIA,
BPH,
Biotechnology,
Eye,
Prescription,
Bluewater,
Pharmacy,
Master service agreement,
Acquisition,
Patient,
Tadalafil,
Physician,
Finasteride,
Capital,
Pain management,
Growth,
Cardiology,
FDA,
Letter,
Urology,
Pharmaceutical industry,
Management,
Sales,
Health insurance In recent months, Blue Water Biotech, Inc. (“Blue Water”) has evolved from a preclinical vaccine development company to a commercial stage pharmaceutical company after the purchase of several FDA approved assets spanning multiple treatment areas.
Key Points:
- In recent months, Blue Water Biotech, Inc. (“Blue Water”) has evolved from a preclinical vaccine development company to a commercial stage pharmaceutical company after the purchase of several FDA approved assets spanning multiple treatment areas.
- While each product has unique considerations for launch and we have analyzed each closely, we have developed a core framework for commercial operations as we progress towards official launch.
- To begin, the core for any successful commercial operation is a dedicated, experienced management team to steer operations and make strategic decisions that will benefit Blue Water in the long run.
- To summarize, the last few months have certainly been an exciting time for Blue Water, filled with acquisitions, growth, and execution.
Marburg virus disease,
Antigen,
Business development,
Partnership,
Travel,
Senior,
University of Texas System,
BPH,
Mpox,
Bluewater,
Infection,
Research,
Testosterone (medication),
Marketing,
Biotechnology,
Congress,
Development,
Acquisition,
Administration,
Streptococcus,
University,
Growth,
FDA,
Conference,
Blue,
Pharmaceutical industry,
Vaccine,
Chlamydia CINCINNATI, May 12, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biotechnology company spanning multiple sectors, today announced its financial results for the quarter ended March 31, 2023 and provided an update on recent business developments and Company progress.
Key Points:
- CINCINNATI, May 12, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biotechnology company spanning multiple sectors, today announced its financial results for the quarter ended March 31, 2023 and provided an update on recent business developments and Company progress.
- Following this acquisition, Blue Water announced in April 2023 that the Company changed its corporate name to Blue Water Biotech, Inc. to reflect its transition into a commercial-stage company.
- In February 2023, Blue Water announced the appointment of seasoned commercial operations leader Frank Jaeger as Senior Vice President of Marketing and Business Development.
- Throughout the first quarter of 2023 and beyond, Blue Water management presented its corporate overview and Company updates at key investor, financial, and scientific conferences to highlight the value story of the Blue Water pipeline and target leaders within the investment community.
At the conference, Blue Water management will present a corporate overview and highlight its launch plan for ENTADFI®, an FDA-approved treatment for benign prostatic hyperplasia (“BPH”) that counteracts negative sexual side effects seen in men on alternative BPH therapies.
Key Points:
- At the conference, Blue Water management will present a corporate overview and highlight its launch plan for ENTADFI®, an FDA-approved treatment for benign prostatic hyperplasia (“BPH”) that counteracts negative sexual side effects seen in men on alternative BPH therapies.
- “Following our purchase of ENTADFI® in April, we are excited to share our launch strategy with the investment community,” said Joseph Hernandez, Chairman and Chief Executive Officer of Blue Water.
- “We believe ENTADFI® has the potential to transform the BPH space and positively impact the lives of millions of men, and we look forward to sharing our strategy with all in attendance.”
Blue Water management will be available during the conference for one-on-one meetings.
- Interested parties may request a one-on-one meeting at [email protected] or contact Blue Water at (513) 620-4101.
Retrieved on:
Wednesday, April 26, 2023
University,
Johns Hopkins Hospital,
BPH,
Johns Hopkins,
Water,
American Urological Association,
MBA,
Bluewater,
Private practice,
Interest,
Business administration,
Patient,
Knowledge,
Master of Business Administration,
FDA,
Therapy,
Blue,
Prostate cancer,
Pharmaceutical industry,
Nursing CINCINNATI, April 26, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biotechnology company spanning multiple sectors, today announced the appointment of Jay Newmark, M.D., MBA as the Company’s Chief Medical Officer.
Key Points:
- CINCINNATI, April 26, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biotechnology company spanning multiple sectors, today announced the appointment of Jay Newmark, M.D., MBA as the Company’s Chief Medical Officer.
- Blue Water currently owns ENTADFI®, an FDA-approved treatment for BPH that counteracts negative sexual side effects seen in men on alternative BPH therapies.
- Dr. Newmark’s appointment will support Blue Water’s upcoming launch of ENTADFI® and he will work closely with Blue Water management to ensure BPH patients are able to receive proper access to treatment.
- Interested parties may request a one-on-one meeting at [email protected] or contact Blue Water at (513) 620-4101.
Business development,
Senior,
BPH,
Water,
Quality of life,
American Urological Association,
Prescription,
Bluewater,
Marketing,
Interest,
Patient,
Risk,
FDA,
Pharmaceutical industry CINCINNATI, April 25, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biotechnology company spanning multiple sectors, today announced that Blue Water management will attend the American Urological Association (“AUA”) Annual Meeting 2023 in Chicago, IL from April 28th to May 1st, 2023, to promote its asset ENTADFI®, an FDA-approved treatment for benign prostatic hyperplasia (“BPH”).
Key Points:
- CINCINNATI, April 25, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biotechnology company spanning multiple sectors, today announced that Blue Water management will attend the American Urological Association (“AUA”) Annual Meeting 2023 in Chicago, IL from April 28th to May 1st, 2023, to promote its asset ENTADFI®, an FDA-approved treatment for benign prostatic hyperplasia (“BPH”).
- “This conference brings together the top urology leaders from around the country, and we are thrilled to attend to promote ENTADFI®,” said Hernandez.
- Blue Water management will be available during the conference for one-on-one meetings and can be found at booth 439.
- Interested parties may request a one-on-one meeting at [email protected] or contact Blue Water at (513) 620-4101.
Vaccine,
Marburg virus disease,
Business development,
Senior,
University of Texas System,
Marketing,
BPH,
Bluewater,
Infection,
Acquisition,
Streptococcus,
University,
Knowledge,
FDA,
Pharmaceutical industry,
Chlamydia CINCINNATI, April 24, 2023 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“Blue Water” or the “Company”), a biopharmaceutical company developing transformational therapies to address significant global health challenges, today announced that it has changed its corporate name to Blue Water Biotech, Inc.
Key Points:
- CINCINNATI, April 24, 2023 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“Blue Water” or the “Company”), a biopharmaceutical company developing transformational therapies to address significant global health challenges, today announced that it has changed its corporate name to Blue Water Biotech, Inc.
- The corporate name change follows the Company’s recent acquisition of ENTADFI®, an FDA-approved treatment for benign prostatic hyperplasia (“BPH”), which has commenced Blue Water’s transition into a commercial-stage biotechnology company.
- “Our recent purchase of ENTADFI® is transforming Blue Water into a commercial-stage biotechnology company and this name change is an exciting reflection of that progress,” said Joseph Hernandez, Chairman and Chief Executive Officer of Blue Water.
- Additionally, Blue Water is developing a universal influenza vaccine and multiple vaccines using its virus-like particle technology, including Marburg virus disease.
